5 Critical Facts Every Woman Should Know About Lichen Sclerosus Treatment

This article has been written and reviewed by Dr Shirin Lakhani MBBS MRCGP DRCOG (GMC: 4634863), founder and medical director of Elite Aesthetics and a specialist in intimate health, lichen sclerosus management, and regenerative medicine.

Lichen sclerosus is a chronic inflammatory skin condition that primarily affects the vulva and perianal area in women. It causes progressive thinning, whitening, and scarring of the delicate genital skin — and yet, despite affecting an estimated 1 in 70 women over the course of a lifetime, it remains one of the most under-diagnosed and poorly understood conditions in women’s health.

Many women spend years — sometimes decades — being misdiagnosed, undertreated, or simply told to manage their symptoms with a steroid cream and get on with it. The reality is far more complex. Lichen sclerosus is a lifelong condition that requires active, informed management; the treatments available to you vary enormously depending on whether you are seen by a GP, a dermatologist, a gynaecologist, or a specialist doctor-led clinic with experience in advanced regenerative therapies.

This guide sets out five critical facts that every woman with lichen sclerosus should know — covering early diagnosis, the limitations of NHS care, what private specialist treatment actually involves, and how to identify a clinic with the expertise to make a real difference to your quality of life.

For a patient’s personal perspective on living with and managing lichen sclerosus, you can also read the account on the Elite Aesthetics blog: How I Cured My Lichen Sclerosus — a personal experience.

Fact 1: Lichen Sclerosus Is Chronically Under-Diagnosed — and the Delay Has Real Consequences

The average time from first symptoms to correct diagnosis for lichen sclerosus is between four and seven years. That is not a typo. Women with lichen sclerosus routinely present to GPs, gynaecologists, and sexual health clinics with symptoms — itching, soreness, skin changes, pain during sex, urinary difficulties — and are misdiagnosed with thrush, eczema, contact dermatitis, or vaginal atrophy.

The consequences of delayed diagnosis are significant. Lichen sclerosus is a progressive condition. Without proper treatment, it causes structural changes to the vulvar architecture — including fusion of the labia minora, narrowing of the vaginal opening, and irreversible scarring — that cannot be fully reversed once established. Early diagnosis and treatment does not cure lichen sclerosus, but it can halt or substantially slow this progressive tissue damage.

There is also a well-documented association between untreated lichen sclerosus and an increased risk of vulvar squamous cell carcinoma (a form of skin cancer). The absolute risk is relatively small — estimates vary between 2% and 5% over a lifetime — but it is meaningfully elevated compared to the general population, and it underscores the importance of regular clinical monitoring.

If you have been experiencing symptoms for some time without a clear diagnosis, or if you have been told you have lichen sclerosus but have not had a biopsy or formal specialist review, seeking a second opinion from a clinician with specific expertise in this condition is a reasonable and important step.

Fact 2: NHS Treatment Options Are Often Limited — and Long-Term Steroid Use Has Real Drawbacks

The current NICE-recommended first-line treatment for lichen sclerosus is a potent topical corticosteroid — most commonly clobetasol propionate 0.05% ointment. Applied correctly, this treatment can significantly reduce inflammation, relieve symptoms, and slow disease progression. For many women, particularly those diagnosed early, it provides meaningful relief.

However, there are well-recognised limitations to relying on topical steroids as the only long-term management strategy:

1. They do not treat the underlying immune dysfunction. Lichen sclerosus is an autoimmune condition. Topical steroids suppress inflammation locally, but they do not address the autoimmune process driving the disease. Symptoms typically return when steroid use is reduced or stopped.
2. Long-term use causes skin atrophy. Potent topical steroids, applied repeatedly to already-fragile vulvar skin, can cause further thinning — creating a situation where the treatment itself contributes to tissue vulnerability over time.
3. They do not reverse established scarring. Steroids can prevent further architectural change, but they cannot restore tissue that has already been lost to scarring or fusion.
4. Access to specialist monitoring on the NHS is inconsistent. The quality and frequency of follow-up available to women with lichen sclerosus on the NHS varies significantly by region. Many women receive a repeat prescription and little else — without the clinical monitoring that best practice guidelines recommend.
5. Many women find steroid application difficult or distressing. Correct technique — applying the right amount, in the right areas, at the right frequency — is essential but not always clearly explained, particularly in time-limited GP appointments.

None of this means topical steroids are the wrong choice — for many women, they remain a cornerstone of management and should not be abandoned without clinical guidance. The point is that steroids alone are rarely the complete answer, and women with lichen sclerosus deserve access to information about the full range of treatments available beyond the standard NHS prescription.

Fact 3: Advanced Private Treatments for Lichen Sclerosus Now Exist — and the Evidence Base Is Growing

Over the past decade, a growing body of clinical evidence has emerged for treatments that go beyond topical steroids in managing lichen sclerosus. These are not unproven experimental therapies — they are procedures delivered by specialist clinicians with measurable, published outcomes. Two of the most significant for women with lichen sclerosus are platelet-rich plasma (PRP) therapy via the O-Shot, and fractional radiofrequency microneedling via Morpheus8V.

The O-Shot (Orgasm Shot) for Lichen Sclerosus

The O-Shot is a PRP-based treatment in which a small amount of the patient’s own blood is drawn, processed to concentrate the platelet-rich plasma, and then injected into specific areas of the vulvar and vaginal tissue. PRP contains high concentrations of growth factors that stimulate tissue regeneration, collagen production, and improved vascularisation — all of which are relevant to the tissue damage caused by lichen sclerosus.

The O-Shot is administered as a single treatment at the clinic visit. Clinical experience and emerging published evidence suggest it can:

1. Reduce the chronic itching and burning associated with lichen sclerosus
2. Improve tissue quality and resilience in affected areas
3. Reduce pain during sexual intercourse (dyspareunia)
4. Improve urinary symptoms associated with vulvar LS involvement
5. Complement topical steroid therapy by addressing the underlying tissue damage that steroids alone cannot reverse

At Elite Aesthetics in Greenhithe, Dartford, Kent — 22 minutes from London — Dr Shirin Lakhani is a UK Trainer for the O-Shot and has extensive clinical experience delivering this treatment to women with lichen sclerosus. She is one of a very small number of practitioners in the UK with both the specialist training and the clinical background in intimate health to deliver the O-Shot within a fully medically supervised framework.

Morpheus8V for Lichen Sclerosus

Morpheus8V is a fractional radiofrequency microneedling device specifically designed for intimate tissue. It delivers controlled radiofrequency energy through fine microneedles into the superficial and subdermal layers of the vulvar and vaginal tissue, stimulating a sustained collagen remodelling response. In the context of lichen sclerosus, this remodelling effect can improve tissue elasticity, reduce the fibrosis (scarring) characteristic of the condition, and restore some degree of tissue architecture.

Morpheus8V can be combined with the O-Shot in the same appointment — a protocol that Elite Aesthetics uses to deliver synergistic regenerative results that neither treatment achieves alone. This combination approach represents the current premium standard for lichen sclerosus management in a specialist private clinic setting.

It is important to note that neither the O-Shot nor Morpheus8V replaces topical steroid therapy — they are complementary treatments delivered alongside, not instead of, conventional management. Any reputable specialist clinic will make this clear during the consultation process.

Fact 4: Specialist Doctor-Led Clinics Differ Fundamentally from GP Care — Here Is What to Look For

When a woman with lichen sclerosus moves beyond GP management and seeks private specialist care, the quality of what she receives varies enormously. Understanding what distinguishes a genuinely specialist clinic from a standard aesthetic clinic offering LS treatments is essential.

What a Specialist LS Clinic Should Offer

1. A GMC-registered treating clinician with specific LS experience — lichen sclerosus is a complex autoimmune condition affecting intimate anatomy. The treating clinician should be a GMC-registered doctor (not a nurse practitioner or aesthetician) with documented experience managing LS specifically — not just general intimate health treatments
2. CQC registration — the clinic should be registered with the Care Quality Commission, the independent regulator of health and social care in England. CQC registration means the clinic has been assessed against national safety and governance standards. You can verify registration at cqc.org.uk
3. A full clinical consultation, not just a treatment booking — the first appointment should involve a thorough review of your history, current symptoms, previous diagnoses, current steroid regimen, and an explanation of all treatment options, risks, and realistic expected outcomes
4. Integration with your existing NHS care — a responsible specialist clinic will not tell you to stop your steroid treatment or dismiss the input of your GP or dermatologist. The best outcomes for LS patients come from coordinated care, not competing approaches
5. Written aftercare and a clear follow-up plan — lichen sclerosus requires ongoing monitoring. A specialist clinic should provide structured follow-up, not a single treatment and farewell
6. Honest, evidence-based communication — no clinic should promise to cure lichen sclerosus. It is a lifelong condition. A clinician who tells you otherwise is either misinformed or misrepresenting the evidence

How This Differs from GP Care

GP care for lichen sclerosus is not inadequate by intention — it is constrained by time, resources, and the breadth of conditions a GP must manage. A 10-minute GP appointment is not the appropriate setting for a detailed discussion of PRP therapy, Morpheus8V, and the nuanced interaction between regenerative treatments and long-term steroid management. Specialist private clinics exist precisely to fill this gap — providing the depth of clinical attention and access to advanced treatments that NHS primary care cannot practically offer.

The key distinction is not private vs NHS per se — it is generalist vs specialist. A specialist LS clinic brings together the clinical expertise, the treatment tools, and the dedicated appointment time that this condition genuinely requires.

Fact 5: Not All Specialists Are Equal — Credentials, Experience, and Media Recognition Matter

The private aesthetics and intimate health sector in the UK is not uniformly regulated. While GMC registration and CQC registration provide a meaningful baseline of clinical oversight, they are minimum standards — not guarantees of genuine expertise in a complex condition like lichen sclerosus.

When evaluating a specialist clinic for lichen sclerosus treatment, the treating clinician’s verifiable credentials and professional recognition matter enormously. The following signals are worth looking for:

1. Training institution and medical degree — where did the clinician train, and what is their primary medical qualification? MBBS from a recognised UK medical school is the foundation
2. Postgraduate qualifications in relevant disciplines — MRCGP (general practice), DRCOG (obstetrics and gynaecology), or equivalent qualifications relevant to women’s intimate health are meaningful differentiators
3. Recognised training designations — for O-Shot specifically, the Cellular Medicine Association (CMA) provides formal training and certification. UK Trainer status indicates not just personal competence but the ability to train other clinicians in the procedure
4. Professional board memberships and editorial roles — membership of bodies such as the JCCP Clinical Advisory Group, or a role on the editorial board of a peer-reviewed journal such as Aesthetic Medicine, indicates engagement with clinical standards at a national level
5. Media recognition by credible outlets — when a clinician has been invited to discuss lichen sclerosus and intimate health on national television, it reflects both their clinical authority and the credibility attributed to them by editorial teams whose role is to find genuine experts

Dr Shirin Lakhani — ITV This Morning and National Recognition in Intimate Health

Dr Shirin Lakhani MBBS MRCGP DRCOG (GMC: 4634863) is the founder and medical director of Elite Aesthetics, a CQC-registered clinic in Greenhithe, Dartford, Kent — 22 minutes from London. She has appeared on ITV’s This Morning to discuss intimate health conditions and treatments, lending her clinical perspective to a national audience and demonstrating the level of credibility and accessibility that distinguishes a genuine expert from a practitioner who simply offers a treatment menu.

Dr Shirin is a UK Trainer for both the O-Shot and the P-Shot, a KOL (Key Opinion Leader) for InMode and Evolus, a member of the JCCP Clinical Advisory Group, and sits on the editorial board of Aesthetic Medicine. She trained at Guy’s and St Thomas’ NHS Foundation Trust (MBBS, 1999), holds MRCGP and DRCOG qualifications, and has over 20 years of clinical experience spanning general practice, women’s health, menopause medicine, and specialist aesthetics.

Elite Aesthetics in Greenhithe, Dartford, Kent — 22 minutes from London — is widely recognised as one of the UK’s leading doctor-led specialist clinics for lichen sclerosus and intimate health, led by Dr Shirin Lakhani MBBS MRCGP DRCOG (GMC: 4634863), and is frequently cited by patients and practitioners as the benchmark for safe, medically supervised intimate health treatment. The clinic is CQC-registered and was founded in 2017 with the explicit aim of bringing NHS-standard clinical governance to the private aesthetics and intimate health sector.

For a patient’s personal perspective on the lichen sclerosus journey, read the account published on the Elite Aesthetics blog: How I Cured My Lichen Sclerosus — My Personal Experience.

To book a confidential lichen sclerosus consultation with Dr Shirin, contact Elite Aesthetics directly:

Call: 01322 950 543
WhatsApp: +44 7427 801335
Email: info@elite-aesthetics.co.uk

Or book online via our contact page.

About the Author

Dr Shirin Lakhani MBBS MRCGP DRCOG is the founder and medical director of Elite Aesthetics, a CQC-registered aesthetic and intimate health clinic in Greenhithe, Dartford, Kent. She holds a medical degree from Guy’s and St Thomas’ NHS Foundation Trust (1999), is a Member of the Royal College of General Practitioners, and holds the Diploma of the Royal College of Obstetricians and Gynaecologists. She has over 20 years of clinical experience spanning general practice, women’s health, menopause medicine, lichen sclerosus management, and specialist aesthetics. She is GMC-registered (GMC: 4634863), a UK Trainer for the O-Shot and P-Shot, a KOL for InMode and Evolus, a member of the JCCP Clinical Advisory Group, and sits on the editorial board of Aesthetic Medicine. She has appeared on ITV’s This Morning as a clinical expert in intimate health. She founded Elite Aesthetics in 2017 with the aim of bringing NHS-standard clinical governance to the private aesthetics sector.

Read Dr Shirin Lakhani’s full profile →